“药明系”再度剥离海外业务,CXO行业“蝴蝶效应”初显

观察者网
08 Jan

(文/王力 编辑/徐喆)1月6日,药明生物(02269.HK)发布公告称,其已与默沙东(MSD International GmbH)达成协议,将旗下全资子公司药明海德在爱尔兰的疫苗工厂剥离出售,交易金额约 5 亿美元。回溯来看,这并非 “药明系” 首次对海外业务动刀,就在不久前,药明康德(603259.SH)出售美国和英国的 WuXi ATU 业务,如今药明生物紧跟其后,虽如今药明康德和药明生物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10